CJC-1295 With DAC vs Without DAC
“CJC-1295 with DAC” and “CJC-1295 No DAC” should not be treated as two duration settings of one identical molecule. The published CJC-1295 work identifies an albumin-binding hGRF(1-29) bioconjugate. The commercial term “No DAC” is commonly used for a shorter GHRH analogue without that albumin-binding reactive group. The structural distinction should come before any kinetic comparison.
What defines the published CJC-1295 molecule?
Jetté and colleagues designed hGRF(1-29) analogues carrying a reactive group that could form an in-vivo covalent bond with the free thiol on Cys34 of serum albumin. Their work identified CJC-1295 as a long-lasting GRF analogue and demonstrated albumin conjugation as the mechanism used to extend exposure in rats. PubMed.
Albumin binding is therefore not a minor optional label. It is a defining structural/pharmacokinetic feature of the molecule described in that CJC-1295 publication.
What “No DAC” means in the Core Research catalogue
The Core Research CJC-1295 No DAC 10mg listing is a Modified-GRF(1-29)-type research product without the albumin-binding DAC feature. Research on GHRF(1-29) analogues shows that amino-acid substitutions can change receptor binding, potency and proteolytic stability. PubMed.
The exact substitutions and chemical form of a supplied “No DAC” product should be confirmed from its applicable specification. The marketing name alone does not make it identical to every historical GHRF(1-29) analogue.
Structural comparison
| Feature | Without DAC / Modified-GRF-type material | Published CJC-1295 albumin-binding analogue |
|---|---|---|
| Core research family | Stabilised hGRF(1-29)-type analogue | hGRF(1-29)-based bioconjugate |
| Albumin-binding reactive group | Absent by definition of the “No DAC” catalogue label | Present; designed for covalent attachment to albumin Cys34 |
| Main experimental distinction | Shorter exposure controlled by the unconjugated analogue’s own stability/clearance | Exposure extended through albumin bioconjugation |
| Can sequence/mass be transferred between them? | No. The exact molecular form must be specified separately. | |
Why fixed half-life numbers are risky
The current literature spans different analogues, species, formulations and assay methods. A single “30-minute versus 8-day” table can look precise while silently combining values from non-equivalent materials and models. This revised comparison therefore keeps the robust conclusion—albumin bioconjugation extends exposure—without presenting one universal half-life as a product specification.
Important comparator limit: The Jetté et al. (2005) bioconjugation experiments evaluated an albumin-reactive GHRH analogue in their defined models; they did not test the actual Core Research “No DAC” lot against that bioconjugate in a matched study. The experimental comparison with native hGRF(1–29) must not be relabelled as a measured half-life difference for every Modified-GRF-type or No-DAC material. Species, sequence, chemical form and assay method must match before kinetic values are compared.
GHRH-receptor research remains a shared context
Both classes are designed around GHRH biology and GHRH-receptor activation, but shared receptor context does not make their time courses or study designs interchangeable. The albumin-bound analogue is useful when the experiment concerns sustained exposure; an unconjugated analogue is useful when the experiment requires a more temporally bounded GHRH-receptor perturbation. That is a study-design distinction, not a recommendation for use in people.
Combination research with Ipamorelin
Core Research also lists CJC-1295 No DAC + Ipamorelin 10mg, a two-component preparation. The constituents address different receptor classes. Their separate pharmacology provides a rationale for studying them together, but it does not prove supra-additive biological effects or establish synergy in the commercial blend.
Analytical and nomenclature checklist
- State whether the material contains an albumin-binding DAC/reactive group.
- State the exact peptide sequence and terminal modifications used in the experiment.
- Do not copy molecular mass or pharmacokinetics from the DAC molecule to a No-DAC material.
- Keep product/lot analytical evidence separate from literature pharmacology.
- For blends, identify each constituent rather than using “CJC” as a complete analytical description.
Research-use boundary
This page explains molecular and study-design distinctions. It does not provide dosing, scheduling, administration or hormone-manipulation guidance. Core Research products are supplied for laboratory research use only, not for human or veterinary use.
Selected references
- Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PMID 15817669.
- Synthesis and in-vitro bioactivity of hGRF(1-29) analogues substituted with single D-amino acids. PMID 3122736.